Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacinresistant pathogens: Results from the ASPECT-cUTI trial

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 7, 2016, Pages 2014-2021

  Huntington, Jennifer A ^a   Sakoulas, George ^b   Umeh, Obiamiwe ^a   Cloutier, Daniel J ^a   Steenbergen, Judith N ^a   Bliss, Caleb ^a   Goldstein, Ellie J C ^c,d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c R M ALDEN RESEARCH LABORATORY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOLOZANE PLUS TAZOBACTAM; LEVOFLOXACIN; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CLEARANCE; BACTERIUM CULTURE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENTEROBACTERIACEAE; ERADICATION THERAPY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; PATHOGENESIS; PHASE 3 CLINICAL TRIAL; POPULATION; POST HOC ANALYSIS; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT INFECTION; URINE CULTURE; ADOLESCENT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; ENTEROBACTERIACEAE INFECTIONS; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; CEPHALOSPORINS; DOUBLE-BLIND METHOD; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; LEVOFLOXACIN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PENICILLANIC ACID; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 84979072369     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw053     Document Type: Article

References (33)

1. Grabe M, Bartoletti R, Bjerklund-Johansen TE et al. Guidelines on Urological Infections. European Association of Urology. http://uroweb.org/wp-content/uploads/Urological-Infections-2010.pdf
2. Sievert DM, Ricks P, Edwards JR et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34: 1-14
3. Zimlichman E, Henderson D, Tamir O et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med 2013; 173: 2039-46
4. Nicolle LE. Complicated urinary tract infection in adults. Can J Infect Dis Med Microbiol 2005; 16: 349-60
5. Tandogdu Z, Cek M, Wagenlehner F et al. Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study. World J Urol 2014; 32: 791-801
6. Wagenlehner FM, Cek M, Naber KG et al. Epidemiology, treatment and prevention of healthcare-associated urinary tract infections. World J Urol 2012; 30: 59-67
7. Spoorenberg V, Hulscher ME, Akkermans RP et al. Appropriate antibiotic use for patients with urinary tract infections reduces length of hospital stay. Clin Infect Dis 2014; 58: 164-9
8. Neidell MJ, Cohen B, Furuya Y et al. Costs of healthcare-and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect Dis 2012; 55: 807-15
9. MacVane SH, Tuttle LO, Nicolau DP. Impact of extended-spectrum β-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. J Hosp Med 2014; 9: 232-8
10. Lee SS, Kim Y, Chung DR. Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis. J Infect 2011; 62: 159-64
11. Hooton TM, Bradley SF, Cardenas DD et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2010; 50: 625-63
12. Cek M, Tandogdu Z, Wagenlehner F et al. Healthcare-associated urinary tract infections in hospitalized urological patients-a global perspective: results from the GPIU studies 2003-2010.World J Urol 2014; 32: 1587-94
13. Sader HS, Farrell DJ, Flamm RK et al. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intraabdominal and urinary tract infections in European and United States hospitals (2012). J Infect 2014; 69: 266-77
14. Tran JH, Jacoby GA. Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci USA 2002; 99: 5638-42
15. Lautenbach E, Strom BL, Bilker WB et al. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001; 33: 1288-94
16. Bouchillon S, Hoban DJ, Badal R et al. Fluoroquinolone resistance among Gram-negative urinary tract pathogens: global smart program results, 2009-2010. Open Microbiol J 2012; 6: 74-8
17. Hoban DJ, Lascols C, Nicolle LE et al. Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extendedspectrum β-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009-2010. Diagn Microbiol Infect Dis 2012; 74: 62-7
18. Chien SC, Wong FA, Fowler CL et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 885-8
19. Langtry HD, Lamb HM. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Drugs 1998; 56: 487-515
20. Zerbaxa [prescribing information]. Lexington, MA: Cubist Pharmaceuticals, 2014
21. Zhanel GG, Chung P, Adam H et al. Ceftolozane/tazobactam: a novel cephalosporin/b-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli. Drugs 2014; 74: 31-51
22. Farrell DJ, FlammRK, Sader HS et al. Antimicrobial activity of ceftolozanetazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012). Antimicrob Agents Chemother 2013; 57: 6305-10
23. Wagenlehner FM, Umeh O, Steenbergen J et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 2015; 385: 1949-56
24. Clinical and Laboratories Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement M100-S22. CLSI, Wayne, PA, USA, 2012
25. Johnson JR, Johnston B, Clabots C et al. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 2010; 51: 286-94
26. Bouchillon SK, Badal RE, Hoban DJ et al. Antimicrobial susceptibility of inpatient urinary tract isolates of Gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011. Clin Ther 2013; 35: 872-7
27. Labreche MJ, Frei CR. Declining susceptibilities of Gram-negative bacteria to the fluoroquinolones: effects on pharmacokinetics, pharmacodynamics, and clinical outcomes. Am J Health Syst Pharm 2012; 69: 1863-70
28. Wagenlehner FM, WeidnerW, Naber KG. Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsis. Clin Pharmacokinet 2007; 46: 291-305
29. Drusano GL, Preston SL, Fowler C et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004; 189: 1590-7
30. Chen YH, Ko WC, Hsueh PR. Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections. Expert Opin Pharmacother 2013; 14: 587-96
31. Rafat C, Debrix I, Hertig A. Levofloxacin for the treatment of pyelonephritis. Expert Opin Pharmacother 2013; 14: 1241-53
32. Briongos-Figuero LS, Gomez-Traveso T, Bachiller-Luque P et al. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum β-lactamase (ESBL)-producing enterobacteria. Int J Clin Pract 2012; 66: 891-6
33. Spadafino JT, Cohen B, Liu J et al. Temporal trends and risk factors for extended-spectrum β-lactamase-producing Escherichia coli in adults with catheter-associated urinary tract infections. Antimicrob Resist Infect Control 2014; 3: 39